Human parvovirus B19 infection in HIV-positive patients

Aguiar, Fábio Silva; Lopes, Daniella P.; Bazin, Anna Ricordi; Setúbal, Sérgio; Cohen, B. J.; Nascimento, Jussara Pereira do

doi:10.1590/s0037-86822001000300002

Cited by 9 publications

(7 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…His blood counts were unexceptional, except for a relatively low hematocrit in January 1999 and the increased medium corpuscular volume commonly observed in patients taking zidovudine. This patient was among an HIV-positive cohort followed by us in a previous study 1 , in which he had been repeatedly found reactive for serum IgG against parvovirus B19. On that occasion (November 1997) his serum dot blot and IgM against parvovirus B19 were both negative.…”

mentioning

confidence: 96%

Clinical presentation of parvovirus B19 infection in HIV-infected patients with and without AIDS

Setúbal

Jorge-Pereira

Sant'Anna

et al. 2003

Rev. Soc. Bras. Med. Trop.

Self Cite

View full text Add to dashboard Cite

mentioning

confidence: 96%

Clinical presentation of parvovirus B19 infection in HIV-infected patients with and without AIDS

Setúbal

Jorge-Pereira

Sant'Anna

et al. 2003

Rev. Soc. Bras. Med. Trop.

Self Cite

View full text Add to dashboard Cite

“…The prevalence and severity of anemia increase as the HIV infection advances to AIDS 21 . Several causes of anemia have been described in HIV patients such as drugs (zidovudine, ganciclovir, trimethoprim-sulfamethoxazole), lymphomas, direct effect of HIV on bone marrow cells and co-infection with mycobacteria, malaria or B19V 27 . In this study we excluded HIV patients on HAART because of the influ-ence some of these drugs may have on the status of anemia in the individual.…”

Section: Discussionmentioning

confidence: 99%

“…However, Patients with a CD4 count greater than 300 cells/µl have been shown to be capable of producing neutralizing antibodies. Persistent infections are also more common among patients with advanced immunodeficiency 27 . Therefore, detecting IgG may not be definitive of persistent infection, considering the impaired ability to produce neutralizing antibodies against B19V especially in some HIV patients 21 .…”

Section: Discussionmentioning

confidence: 99%

Parvovirus B19 DNA detection in treatment-naïve HIV anemic patients in Lagos, Nigeria: a case control study

et al. 2020

View full text Add to dashboard Cite

Background: Parvovirus B19 (B19) has tropism for cells of the erythroid lineage, which may lead to transient inhibition of erythropoiesis. Several studies and case reports suggested that B19 infection may contribute significantly to severe chronic ane- mia in HIV infected persons. Objective: To detect parvovirus B19 DNA in treatment-naïve HIV patients. Methods: This was a case control retrospective study. One hundred nineteen anemic and 81 non-anemic treatment-naïve HIV infected patients participated in the study at the Lagos University Teaching Hospital, Lagos, Nigeria. Polymerase chain reaction was used to detect B19 DNA. Results: Out of 200 patients analysed, 13(6.5%) had parvovirus B19 DNA. Eight HIV patients with anemia had B19 DNA while five non-anemic HIV patients had B19 DNA. This suggests that the presence of B19 DNA in the blood of HIV positive individuals may contribute to anemia because the majority (61.5%) who were positive for B19 DNA had anemia as compared to the non-anemic control group (38.5%). Conclusion: This study shows that the presence of B19 DNA in anemic HIV infected patients is not associated with chronic anaemia in HIV infection because no significant association exist. Keywords: Parvovirus B19; anemia; human immunodeficiency virus; polymerase chain reaction.

show abstract

“…Immunoglobulin treatment can cure the infection and, sometimes and paradoxically, transiently worsen the clinical picture by triggering immune complex symptoms (Frickhofen et al 1990, Setúbal et al 2003, Young & Brown 2004). Since 1998 we have been studying erythrovirus B19 infection in our HIV infected patients in Hospital Universitário Antônio Pedro (HUAP), Niterói, Rio de Janeiro, Brazil (Aguiar et al 2001, Setúbal et al 2003. We have always considered co-infection infrequent and attributed this to the fact that most of our HIV infected patients were under anti-retroviral therapy.…”

Section: Erythrovirus B19 Infects Erythrocytic Progenitors Transientmentioning

confidence: 99%

“…Since 1998 we have been studying erythrovirus B19 infection in our HIV infected patients in Hospital Universitário Antônio Pedro (HUAP), Niterói, Rio de Janeiro, Brazil (Aguiar et al 2001, Setúbal et al 2003. We have always considered co-infection infrequent and attributed this to the fact that most of our HIV infected patients were under anti-retroviral therapy.…”

mentioning

confidence: 99%

Erythrovirus B19 infection in acquired immunodeficiency syndrome: screening by histopathology, immunohistochemistry, and in situ hybridization

Setúbal

Oliveira

Pires

et al. 2006

Mem. Inst. Oswaldo Cruz

Self Cite

View full text Add to dashboard Cite

Erythrovirus B19 infects erythrocytic progenitors, transiently interrupting erythropoiesis. In AIDS patients it causes chronic anemia amenable to treatment. We looked for evidences of B19 infection in stored bone marrow material from patients with acquired immunodeficiency syndrome. Histological sections were made from stored paraffin blocks from 33 autopsies (39 blocks) and 35 biopsies (45 blocks, 30 patients) performed from 1988 to 2002. They were examined after hematoxylin-eosin (HE) staining, immunohistochemical (IHC), and in situ hybridization. HE revealed intra-nuclear inclusion bodies ("lantern cells") suggesting B19 infection in 19 sections corresponding to 19 of 63 patients examined with this test. Seven of 78 sections subjected to immunohistochemistry were positive, corresponding to 7 of 58 patients examined with this test. Fourteen sections corresponding to 13 of the 20 HE and/or IHC positive patients were subjected to in situ hybridization, with six positives results. Among the 13 patients subjected to the three techniques, only one gave unequivocal positive results in all and was considered a true positive. The frequency of B19 infection (1/63 patients) in the material examined can be deemed low.Key words: parvovirus B19-anemia -chronic-immunodeficiency Erythrovirus B19 infects human erythrocytic progenitor cells, leading to a transient interruption of erythropoiesis. In the immunocompetent host this viral infection is cleared within two weeks as a result of the appearance of serum specific antibodies, and the hematological manifestations are restricted to a slight and asymptomatic decline in the hemoglobin levels. When the antibodies appear there may be symptoms of immune complex disease like arthralgias and exanthema. This is what normally takes place during the common childhood exanthematic disease erythema infectiosum. The course can be quite different in certain kinds of host, like those with hereditary hemolytic anemias (e.g., sickle-cell anemia), in whom an acceptable hematocrit is maintained only through an intense and uninterrupted bone marrow activity. In this context erythrovirus B19 infection usually leads to the rapid onset of a life threatening acute anemia, the so called "transient aplastic crisis". The patient is transfusion-dependent until the appearance of specific antibodies spontaneously clears the infection. A similar situation can be found in the fetus, where normal erythron volume expansion also demands a high activity of the hematopoietic fetal tissues. The sudden interruption of hematopoiesis leads to fetal heart failure and anasarca (hydrops fetalis), which may result in fetal death. In immunocompromised individuals (e.g., HIV-infected patients) erythrovirus infection is not readily cleared and its long persistence leads to chronic anemia. In these patients, intravenous standard immunoglobulin infusions usually end viremia and restore hematopoiesis (de Mayolo & Temple 1990, Mitchell et al. 1990, Gottlieb & Deutsch 1992, Noronha et al. 2005.Erythrovirus B19 was discovered by...

show abstract

Human parvovirus B19 infection in HIV-positive patients

Cited by 9 publications

References 20 publications

Clinical presentation of parvovirus B19 infection in HIV-infected patients with and without AIDS

Clinical presentation of parvovirus B19 infection in HIV-infected patients with and without AIDS

Parvovirus B19 DNA detection in treatment-naïve HIV anemic patients in Lagos, Nigeria: a case control study

Erythrovirus B19 infection in acquired immunodeficiency syndrome: screening by histopathology, immunohistochemistry, and in situ hybridization

Contact Info

Product

Resources

About